Mogelijk gemaakt door 
Translate
Translate
28 March 2024
Scancell Holdings plc
("Scancell" or the "Company")
WG Partners LLP appointed as Joint Broker
Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies for the treatment of cancer, announces that WG Partners LLP was appointed as Joint Broker to the Company on the 3 October 2023.
-ENDS-
|
For further information, please contact: |
|
|
|
|
|
Scancell Holdings plc |
+44 (0) 20 3709 5700 |
|
Professor Lindy Durrant, CEO Dr Jean-Michel Cosséry, Non-Executive Chairman
|
|
|
Stifel Nicolaus Europe Limited (Nominated Adviser and Joint Broker) |
+44 (0) 20 7710 7600 |
|
Nicholas Moore/Samira Essebiyea (Healthcare Investment Banking) Nick Adams/Nick Harland (Corporate Broking)
|
|
|
Panmure Gordon (UK) Limited (Joint Broker) |
+44 (0) 20 7886 2500 |
|
Freddy Crossley/Emma Earl (Corporate Finance) |
|
|
Rupert Dearden (Corporate Broking) |
|
|
WG Partners LLP (Joint Broker) |
+44 (0) 20 3705 9330 |
|
David Wilson/Claes Spang/Sathesh Nadarajah/Erland Sternby |
|
|
ICR Consilium |
+44 (0) 20 3709 5700 |
|
Mary-Jane Elliott/Angela Gray/Lindsey Neville |
|
About Scancell
Scancell is a clinical stage biopharmaceutical company that is leveraging its proprietary research, built up over many years of studying the human adaptive immune system, to generate novel medicines to treat significant unmet needs in cancer. The Company is building a pipeline of innovative products by utilising its four technology platforms: Moditope® and ImmunoBody® for vaccines and GlyMab® and AvidiMab® for antibodies.
Adaptive immune responses include antibodies and T cells (CD4 and CD8), both of which can recognise damaged or infected cells. In order to destroy such cancerous or infected cells, Scancell uses either vaccines to induce immune responses or monoclonal antibodies (mAbs) to redirect immune cells or drugs. The Company's unique approach is that its innovative products target modifications of proteins and lipids. For the vaccines (Moditope® and ImmunoBody®) this includes citrullination and homocitrullination of proteins, whereas its mAb portfolio targets glycans or sugars that are added onto proteins and / or lipids (GlyMab®) or enhances the potency of antibodies and their ability to directly kill tumour cells (AvidiMab®).
For further information about Scancell, please visit: https://www.scancell.co.uk/
